MINI REVIEW article
Front. Oncol.
Sec. Hematologic Malignancies
This article is part of the Research TopicMultiple Myeloma Treatment: On the Brink of Prime TimeView all 5 articles
MRD in Multiple Mieloma: the Clinical Perspective
Provisionally accepted
TOMMASO CARAVITA DI TORITTO1,2*
angela rago1- 1UOSD EMATOLOGIA ASL ROMA 1, Roma, Italy
- 2Azienda Sanitaria Locale Roma 1, Rome, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Minimal residual disease (MRD) has emerged as a key prognostic factor in multiple myeloma (MM), allowing a more accurate evaluation of treatment efficacy beyond conventional complete remission. High-sensitivity techniques, including next-generation flow cytometry (NGF), next-generation sequencing (NGS), and allele-specific oligonucleotide quantitative PCR, enable detection of residual disease at levels of 10⁻⁵–10⁻⁶ (1–4). Achieving MRD negativity is consistently associated with prolonged progression-free survival (PFS) and overall survival (OS) across different disease settings (4,17). In 2024, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee unanimously recognized MRD negativity as a primary endpoint in MM clinical trials, reinforcing its role as a validated surrogate of clinical benefit (34). This review summarizes current MRD detection methods and discusses how MRD assessment, interpreted in the context of recent pivotal clinical trials, may provide a practical framework to guide future treatment strategies in MM.
Keywords: MRD - measurable residual disease, MRD - minimal residual disease, Multipl myelom, prog- nosis, Respons mechanism of electrode
Received: 05 Nov 2025; Accepted: 19 Dec 2025.
Copyright: © 2025 CARAVITA DI TORITTO and rago. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: TOMMASO CARAVITA DI TORITTO
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.